The Science of PARK19A and Your Child's Diagnosis
At a Glance
PARK19A is a DNAJC6-related form of juvenile parkinsonism. Reduced auxilin activity can disrupt the recycling of message-carrying bubbles in brain cells, so children may have movement problems together with developmental delays, seizures, cognitive changes, or swallowing difficulties.
To understand PARK19A, it helps to look deep inside the brain cells (neurons) at how they communicate. Most genetic conditions that cause parkinsonism in children affect how the cell creates energy or cleans up waste. PARK19A is different because it breaks the “recycling system” that allows brain cells to send messages efficiently [1][2].
The Biology: Recycling the “Messenger Bubbles”
Brain cells talk to each other by releasing chemical messengers stored in tiny bubbles called synaptic vesicles. Once a bubble releases its message, the cell must quickly “recycle” it so it can be refilled and used again.
- The Clathrin Coat: To pull a new bubble back into the cell, a protein called clathrin forms a protective “coat” or cage around it [1].
- The Role of Auxilin: This is where the DNAJC6 gene comes in. It provides instructions for a protein called auxilin. Think of auxilin as the “unzipper.” It attaches to the clathrin cage and signals another protein to strip the coat off [1][3].
- The Breakdown: In PARK19A, the cell doesn’t have enough working auxilin. In simplified research models, the clathrin coats stay stuck on the bubbles, preventing them from being recycled. The precise mechanisms of neuronal dysfunction and degeneration remain under study, but it is believed that over time communication breaks down [4][5].
“Pure” vs. “Complex” Parkinsonism
Doctors often use overlapping clinical patterns to categorize movement disorders. Understanding the difference helps explain why PARK19A can look different from typical Parkinson’s disease.
- Primary Motor Parkinsonism: This refers to conditions that primarily cause movement issues (tremors, stiffness, slowness). Genes like PRKN (Parkin), PINK1, and PARK7 often fall into this category, though they can also include non-motor features. Children with these forms often respond well to standard medications [6][7][8].
- Complex (Atypical) Parkinsonism: PARK19A often presents as “complex” because it frequently involves “extra” symptoms like developmental delays, seizures, and cognitive changes that aren’t usually seen in the primary motor forms [5][9].
How Doctors Tell the Difference
Because many rare conditions look similar at first, doctors perform a differential diagnosis—a process of elimination to ensure they have the right answer.
| Condition | Primary Gene | Key Distinguishing Features |
|---|---|---|
| PARK19A | DNAJC6 | Often starts with developmental delay or “losing” skills; may include seizures and swallowing issues [5][9]. |
| PRKN/PINK1 | PRKN, PINK1 | Usually starts later; often predominantly motor; response to medication can be very high [7][8]. |
| PARK14 | PLA2G6 | Often involves eye movement problems and “pyramidal signs” (unusual reflexes or weakness) [10][11]. |
| Kufor-Rakeb | ATP13A2 | May include unique eye movement issues and significant cognitive or psychiatric features [12][13]. |
Knowing that PARK19A is the specific cause allows your medical team to focus on the specific challenges—like seizures or developmental support—that come with this particular “recycling” problem [5].
Common questions in this guide
What is PARK19A, and which gene causes it?
How can a DNAJC6 change affect communication between brain cells?
What symptoms may a child with PARK19A develop?
Why do doctors compare PARK19A with other forms of juvenile parkinsonism?
How can identifying PARK19A help guide my child's care?
Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease.
Gorenberg EL, Chandra SS
Frontiers in neuroscience 2017; (11()):248 doi:10.3389/fnins.2017.00248.
PMID: 28579939 - 2
Impaired pre-synaptic plasticity and visual responses in auxilin-knockout mice.
Cheng X, Tang Y, Vidyadhara DJ, et al.
iScience 2023; (26(10)):107842 doi:10.1016/j.isci.2023.107842.
PMID: 37766983 - 3
Reconstitution of Clathrin Coat Disassembly for Fluorescence Microscopy and Single-Molecule Analysis.
Böcking T, Upadhyayula S, Rapoport I, et al.
Methods in molecular biology (Clifton, N.J.) 2018; (1847()):121-146 doi:10.1007/978-1-4939-8719-1_10.
PMID: 30129014 - 4
Neurodevelopmental and synaptic defects in DNAJC6 parkinsonism, amenable to gene therapy.
Abela L, Gianfrancesco L, Tagliatti E, et al.
Brain : a journal of neurology 2024; (147(6)):2023-2037 doi:10.1093/brain/awae020.
PMID: 38242634 - 5
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
Ng J, Cortès-Saladelafont E, Abela L, et al.
Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.
PMID: 32472658 - 6
Clinical Variability of SYNJ1-Associated Early-Onset Parkinsonism.
Lesage S, Mangone G, Tesson C, et al.
Frontiers in neurology 2021; (12()):648457 doi:10.3389/fneur.2021.648457.
PMID: 33841314 - 7
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
Kasten M, Hartmann C, Hampf J, et al.
Movement disorders : official journal of the Movement Disorder Society 2018; (33(5)):730-741 doi:10.1002/mds.27352.
PMID: 29644727 - 8
Rethinking 'rare' PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology.
Yin EP, Dieriks BV
Journal of Parkinson's disease 2025; (15(1)):41-65 doi:10.1177/1877718X241304814.
PMID: 39973502 - 9
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism.
Pessoa ALS, Guimarães TG, de Castro Dos Santos D, et al.
Movement disorders clinical practice 2026; doi:10.1002/mdc3.70731.
PMID: 42414182 - 10
Clinical Profile and Genetic Composition of Patients With Juvenile Parkinsonism From a Single Tertiary Care Center in India.
Farsana MK, Holla VV, Phulpagar P, et al.
Journal of movement disorders 2026; (19(1)):19-30 doi:10.14802/jmd.25132.
PMID: 40829774 - 11
Case Report: Where is the boundary between autosomal recessive early-onset Parkinson's disease and dystonia-parkinsonism: a case of PLA2G6-associated neurodegeneration.
Li XT, Yuan CX, Lv ZQ, et al.
Frontiers in human neuroscience 2026; (20()):1772073 doi:10.3389/fnhum.2026.1772073.
PMID: 42158583 - 12
ATP13A2 novel mutations causing a rare form of juvenile-onset Parkinson disease.
Suleiman J, Hamwi N, El-Hattab AW
Brain & development 2018; (40(9)):824-826 doi:10.1016/j.braindev.2018.05.017.
PMID: 29903538 - 13
Successful treatment of psychosis in a patient with Kufor-Rakeb syndrome with low dose aripiprazole: a case report.
McNeil-Gauthier AL, Brais B, Rouleau G, et al.
Neurocase 2019; (25(3-4)):133-137 doi:10.1080/13554794.2019.1625928.
PMID: 31232173
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric neurologist and genetics team should interpret DNAJC6 or PARK19A findings and symptoms in context.